Tirzepatide Guide

Tirzepatide is a synthetic peptide medication developed by Eli Lilly. It is based on the natural hormone GIP (glucose-dependent insulinotropic polypeptide) and engineered to also activate the GLP-1 (glucagon-like peptide-1) receptor. Both are incretin hormones released by the gut after eating that help regulate appetite and blood sugar.

It is sold under two brand names with different FDA-approved uses: Mounjaro for type 2 diabetes and Zepbound for chronic weight management and obstructive sleep apnea in adults with obesity. Both contain the same active ingredient.

Tirzepatide acts on GIP and GLP-1 receptors in the brain, pancreas, and digestive system. The combined effect:

• Reduces appetite and cravings and increases fullness, so people naturally eat less.
• Slows stomach emptying, which helps fullness last longer after meals.
• Increases insulin release when blood sugar is high and lowers glucagon, improving blood sugar control.

Activating two receptors instead of one is thought to be part of why tirzepatide has produced greater average weight loss than GLP-1-only medications in clinical trials.

• Mounjaro: improving blood sugar control in adults with type 2 diabetes, alongside diet and exercise.
• Zepbound: chronic weight management in adults with obesity, or with overweight and at least one weight-related condition, alongside diet and activity.
• Zepbound: moderate-to-severe obstructive sleep apnea in adults with obesity.

Use outside these approvals is considered off-label and requires physician judgment.

Per the FDA-approved labeling, tirzepatide starts at 2.5 mg injected once weekly for 4 weeks. The 2.5 mg dose is for starting treatment only and is not a maintenance dose. The dose is then increased in 2.5 mg steps, at least 4 weeks apart, based on response and tolerance, up to a maximum of 15 mg weekly. Increasing slowly reduces nausea and other digestive side effects.

Your physician sets your dose and pace. Do not change your dose without guidance.

In SURMOUNT-1, a 72-week trial of 2,539 adults with obesity or overweight without diabetes, average weight loss was about 15 percent at 5 mg, 19.5 percent at 10 mg, and 21 percent at 15 mg, compared with about 3 percent with placebo. All participants also received lifestyle guidance.

Trial averages are not guarantees. Individual results vary with dose, consistency, nutrition, activity, and health history. Weight regain is common after stopping, so a long-term plan matters.

The most common side effects are nausea, diarrhea, vomiting, constipation, abdominal discomfort, and reduced appetite, usually most noticeable when starting or increasing the dose.

Tirzepatide carries a boxed warning about thyroid C-cell tumors seen in rodents. It is not used in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Other serious risks listed in the labeling include pancreatitis, gallbladder problems, low blood sugar when combined with insulin or sulfonylureas, kidney problems from dehydration, serious allergic reactions, and a risk of inhaling stomach contents during anesthesia or sedation. It is not used during pregnancy.

Tirzepatide can make oral birth control pills less effective after starting and after each dose increase. The labeling advises switching to a non-oral method or adding a barrier method for 4 weeks after starting and after each increase.

Semaglutide (Ozempic, Wegovy) activates the GLP-1 receptor only. Tirzepatide activates both GIP and GLP-1. In separate clinical trials, tirzepatide produced larger average weight loss, and some patients tolerate one medication better than the other. The right choice depends on your goals, history, side effects, and access. Learn more in our guide to how semaglutide works.

During the national shortage, compounded versions of tirzepatide were widely available. FDA declared the tirzepatide shortage resolved in December 2024, and the temporary period that allowed widespread compounded copies has ended. Compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality.

If you are offered tirzepatide anywhere, ask exactly what product you are receiving, where it is made, and whether it is the FDA-approved medication.